T1	Participants 69 101	patients with myasthenia gravis.
T2	Participants 111 194	Patients with myasthenia gravis receive pyridostigmine, an anticholinesterase agent
T3	Participants 537 595	patients with myasthenia gravis on pyridostigmine therapy.
T4	Participants 713 829	Medically (oral pyridostigmine) well-controlled adult patients with myasthenia gravis who were posted for thymectomy
T5	Participants 1286 1303	Fourteen patients
T6	Participants 1988 2005	myasthenia gravis
